Tremfya Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application (Plaque Psoriasis, Psoriatic Arthritis (PsA), Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Competition, 2020-2030F

Market Overview

The Global Tremfya Market was valued at USD 3.78 Billion in 2024 and is expected to reach USD 5.87 Billion by 2030 with a CAGR of 7.59%. The Global Tremfya Market is witnessing steady growth, driven by rising demand for targeted biologic therapies in managing chronic autoimmune conditions such as plaque psoriasis and psoriatic arthritis. Tremfya, an IL-23 inhibitor, has gained significant attention due to its high efficacy, favorable safety profile, and convenient dosing schedule, which enhance patient adherence and treatment outcomes. Growing prevalence of these conditions worldwide, coupled with increasing awareness among patients and healthcare professionals about the benefits of targeted immunology therapies, is contributing to the market’s expansion. Pharmaceutical companies are investing in advanced research and clinical trials to explore the broader therapeutic potential of Tremfya, including its application in other inflammatory disorders. Expanding treatment guidelines that recommend biologics for moderate-to-severe cases are further boosting adoption rates.

The market is experiencing a shift toward long-acting biologics that reduce dosing frequency while maintaining therapeutic effectiveness, aligning well with Tremfya’s monthly or quarterly administration schedule. Continuous advancements in biologic drug formulation and delivery systems are supporting better patient compliance and treatment satisfaction. There is also a notable increase in collaborations between pharmaceutical manufacturers and healthcare providers to improve patient education, optimize treatment pathways, and expand access through insurance coverage and reimbursement programs. Competitive dynamics are being shaped by ongoing product innovation, pipeline expansions, and strategic partnerships aimed at enhancing market penetration and addressing unmet needs. Furthermore, the increasing focus on personalized medicine is encouraging the development of targeted therapies like Tremfya, as clinicians seek more precise and effective treatment options for patients with complex immune-mediated diseases.

Despite the promising growth prospects, the Global Tremfya Market faces several challenges. High treatment costs remain a major barrier, particularly in low- and middle-income regions, limiting broader patient access. Patent exclusivity and regulatory requirements for biosimilars may restrict competitive pricing in the near term, prolonging cost-related limitations. Some patients may also experience varying treatment responses, necessitating alternative therapeutic strategies. The market is subject to intense competition from other biologics and small molecule drugs targeting similar pathways, such as IL-17 and TNF inhibitors, which may impact Tremfya’s adoption in certain patient segments. Additionally, the lengthy and complex drug approval process for new indications can delay market expansion opportunities. Addressing these challenges through pricing strategies, patient assistance programs, and continued clinical research will be crucial for sustaining growth in the forecast period.

Key Market Drivers

Rising Prevalence of Chronic Inflammatory Diseases

The rising prevalence of chronic inflammatory diseases such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis is a compelling driver for the Global Tremfya Market. In the United States, psoriasis affects approximately 3.0% of adults, translating to over 7.5 million individuals, according to data from the National Health and Nutrition Examination Survey. Among these, a significant portion go on to develop psoriatic arthritis, which impacts roughly 0.41% of the U.S. adult population, equating to nearly 912,000 adults.

Inflammatory bowel diseases (IBD), encompassing Crohn’s disease and ulcerative colitis, are diagnosed in approximately 721 per 100,000 Americans, or nearly 1 in 100, as reported by the Crohn’s & Colitis Foundation in a comprehensive U.S. population-based study. Strong diagnostic data reinforces the growing burden of these conditions. These diseases are often chronic and debilitating, underscoring the importance of effective long-term treatment strategies. Tremfya’s targeted mechanism of selectively inhibiting the p19 subunit of interleukin-23 addresses the underlying inflammatory pathways more precisely than older systemic therapies. This precision results in favorable safety and efficacy outcomes, making Tremfya an appealing treatment for both clinicians and patients seeking better disease control and improved quality of life.

Rising obesity rates, environmental stressors, and an aging population contribute to increasing incidence and prevalence of these immune-mediated conditions. Healthcare systems emphasize early intervention to prevent disease progression, reduce flare-ups, and minimize complications such as joint damage or gastrointestinal scarring. Demand remains strong for biologics like Tremfya that offer durable remission and reduced dosing frequency. Altogether, the confluence of growing patient populations supported by robust U.S. epidemiological data and Tremfya’s effective, targeted profile is fueling market momentum and positioning it as a preferred therapy in managing chronic inflammatory diseases.

Expansion of Indications and Regulatory Approvals

The expansion of indications and regulatory approvals is transforming the Global Tremfya Market into a multi-therapeutic growth engine, greatly enhancing its commercial potential. Originally cleared in July 2017 for plaque psoriasis, Tremfya gained an additional U.S. approval for active psoriatic arthritis in July 2020. A pivotal breakthrough came in September 2024, when the FDA granted approval for its use in adults with moderately to severely active ulcerative colitis, based on the Phase 2b/3 QUASAR data showing a remarkable endoscopic remission rate of 34–35% at one year compared to just 15% with placebo.

In March 2025, regulatory momentum continued with FDA approval for Crohn’s disease marking Tremfya as the first IL-23 inhibitor offering both subcutaneous and intravenous induction options. In Europe, the MHRA expanded its authorization in May 2025 to include both ulcerative colitis and Crohn’s disease. These approvals extend Tremfya’s clinical applicability and patient reach, strengthening its competitive standing among biologics. Each new regulatory endorsement opens access to previously unmet patient segments, helping diversify revenue and prolong product lifecycle. Broader indication coverage enhances clinical confidence among prescribers, fostering adoption in complex treatment pathways. Deeper penetration into gastroenterological care finally positions Tremfya for growth beyond dermatology. These strategic label extensions and approvals elevate Tremfya from a niche dermatological biologic into a foundational agent across immune-mediated inflammatory diseases. As Tremfya’s footprint expands, the drug secures a resilient market position, a trend set to drive continued momentum through the mid-2020s.

Advancements in Drug Delivery Systems

Advancements in drug delivery systems are a powerful growth driver for the Global Tremfya Market, enhancing both treatment efficacy and patient convenience through technical innovation. Tremfya’s extended maintenance dosing, administered every eight weeks after initial loading, sets a new standard in biologic therapy for chronic inflammatory conditions. User-friendly delivery devices like prefilled syringes and auto-injectors enable self-administration outside clinical settings, reducing patient dependence on medical visits, a benefit particularly valuable in managing lifetime therapies. Improved ergonomic designs, accurate dosing mechanisms, and built-in safety features help address common concerns such as needle anxiety, dosing errors, and injection-related discomfort.

A 2022 analysis of FDA-approved biologics reports that approximately 36% of these therapies are administered via subcutaneous injection, underscoring the critical role of self-injectable formats in modern biologic drug delivery. Stability improvements in Tremfya’s formulation, allowing longer shelf life and less reliance on refrigeration, are facilitating wider distribution especially in areas with limited healthcare infrastructure and unreliable cold chain logistics. Smart delivery technologies that offer digital dose tracking, reminder systems, and secure data capture are further enhancing adherence and enabling real-time monitoring of therapy patterns. These innovations boost patient satisfaction and complement Tremfya’s competitive profile by delivering a consistent, reliable treatment experience. As physicians and patients increasingly seek convenient, effective, and safe therapeutic options, these delivery advancements are key to expanding Tremfya’s market reach and solidifying its position in the biologics arena.

Download Free Sample Report

Key Market Challenges

High Treatment Costs

High treatment costs remain one of the most significant challenges impacting the Global Tremfya Market. Tremfya, being a biologic therapy, involves complex manufacturing processes, stringent quality controls, and advanced biotechnology infrastructure, all of which contribute to its high price point. The expense is further amplified by research and development costs, clinical trial investments, and regulatory compliance requirements. For many patients, particularly in low- and middle-income countries, the price of Tremfya places it beyond financial reach without robust insurance coverage or government subsidy programs. Even in developed markets, patients may face high out-of-pocket expenses, co-payments, or limitations in reimbursement policies, which can result in reduced adoption rates.

Healthcare systems often prioritize cost-effectiveness, and biologics like Tremfya must demonstrate clear value over existing therapies to justify coverage. This economic barrier can lead to delayed treatment initiation, therapy discontinuation, or a preference for cheaper alternatives, even if they are less effective. Pharmaceutical companies face the challenge of balancing innovation with affordability while navigating pricing negotiations with payers. The high treatment cost issue also influences competitive dynamics, as the emergence of biosimilars or alternative biologics with lower prices could erode market share. Addressing this challenge requires strategic pricing, value-based reimbursement models, and expansion of patient assistance programs to make Tremfya more accessible.

Competition from Existing and Emerging Therapies

Competition from existing and emerging therapies presents a significant challenge for the Global Tremfya Market, as the treatment landscape for autoimmune and inflammatory disorders is becoming increasingly crowded. Tremfya, being an IL-23 inhibitor, competes directly with other drugs in the same class, such as Skyrizi (risankizumab) and Ilumya (tildrakizumab), which offer similar efficacy and safety profiles. Beyond IL-23 inhibitors, it also faces strong competition from IL-17 inhibitors like Cosentyx and Taltz, TNF-alpha inhibitors such as Humira and Enbrel, and JAK inhibitors like Rinvoq, which are gaining traction for their oral administration advantage. The presence of multiple therapeutic options gives physicians greater flexibility in treatment selection, often making it harder for a single drug to dominate market share.

Emerging pipeline drugs with novel mechanisms of action also threaten Tremfya’s position, as these candidates may offer improved efficacy, faster onset, or reduced side effects, attracting both physicians and patients. Pricing pressure from biosimilars in other biologic classes may indirectly impact Tremfya’s competitiveness, as payers push for cost-effective alternatives. The need for constant differentiation in terms of clinical benefits, dosing convenience, or patient support programs is critical for sustaining growth in such a competitive environment. Without clear superiority over rivals, Tremfya risks losing market momentum, especially as newer entrants with stronger marketing campaigns and expanded indications enter the market during the forecast period.

Key Market Trends

Increasing Adoption of IL-23 Inhibitors

The increasing adoption of IL-23 inhibitors is emerging as a defining trend in the Global Tremfya Market, driven by the growing recognition of their targeted therapeutic benefits in treating chronic immune-mediated inflammatory diseases. IL-23 inhibitors, such as Tremfya, block the p19 subunit of the interleukin-23 cytokine, a critical driver of inflammation in conditions like plaque psoriasis and psoriatic arthritis. This highly specific mechanism of action offers a favorable efficacy-to-safety ratio, making these drugs an attractive option for both physicians and patients, particularly those who have experienced suboptimal responses or adverse effects with older biologic classes such as TNF-alpha inhibitors or IL-17 blockers. The extended dosing intervals associated with IL-23 inhibitors, often every eight to twelve weeks after initial loading doses, enhance treatment adherence by reducing the frequency of injections, which is a significant advantage for patients managing lifelong conditions.

Clinical trial data and real-world evidence continue to validate the long-term durability of response and low immunogenicity risk, further building confidence in this drug class. Pharmaceutical companies are also expanding the scope of IL-23 inhibitor applications into new indications such as Crohn’s disease and ulcerative colitis, which could substantially broaden their market potential. As prescriber familiarity grows and healthcare systems begin to recognize their long-term cost-effectiveness due to reduced disease flare-ups and improved quality of life, the uptake of IL-23 inhibitors is expected to accelerate. Strategic marketing efforts, patient support programs, and increased payer acceptance are contributing to their growing presence in treatment guidelines, reinforcing the trajectory of sustained adoption for Tremfya and its counterparts in the coming years. This trend reflects a broader shift in autoimmune disease management toward precision-targeted biologics that prioritize sustained remission, minimal side effects, and improved patient convenience.

Shift Toward Long-Acting Biologics

The Global Tremfya Market is witnessing a clear shift toward long-acting biologics, driven by the growing need for improved patient adherence, reduced treatment burden, and enhanced quality of life in chronic disease management. Tremfya’s dosing regimen, which involves a maintenance injection every eight weeks after the initial loading phase, is a key differentiator in the biologics space. This extended dosing interval aligns with patient preferences for fewer clinic visits or self-administrations, making treatment more convenient for individuals managing conditions such as plaque psoriasis and psoriatic arthritis over the long term. Physicians also view long-acting biologics as advantageous, as reduced dosing frequency often correlates with higher adherence rates and better sustained outcomes.

The trend is being supported by advancements in drug formulation technologies that maintain therapeutic efficacy over prolonged periods without compromising safety. From a market perspective, long-acting biologics create competitive advantages for manufacturers by fostering strong patient loyalty, as switching between biologics becomes less appealing when treatment schedules are less demanding. Payers are also beginning to recognize the potential cost-effectiveness of longer dosing intervals, as they can lead to fewer healthcare interactions and reduced overall disease management costs. The growing demand for therapies like Tremfya reflects a broader industry movement toward simplifying chronic disease treatment while maintaining high clinical efficacy, making this trend a major growth catalyst for the market in the coming years.

Segmental Insights

Application Insights

Based on the Application, Plaque Psoriasis emerged as the dominant segment in the Global Tremfya Market in 2024. This is driven by the rising prevalence of this chronic autoimmune condition and the proven efficacy of Tremfya in its management. Plaque psoriasis affects millions of people worldwide, causing significant physical discomfort, visible skin lesions, and emotional distress, which has increased the demand for effective long-term treatment solutions. Tremfya, a selective IL-23 inhibitor, has gained strong adoption due to its ability to deliver rapid skin clearance, sustain results over extended periods, and offer a favorable safety profile compared to some older biologics. Its eight-week maintenance dosing schedule after initial loading doses has enhanced patient adherence and convenience, making it a preferred option among dermatologists and patients seeking consistent relief. Growing awareness about advanced biologic therapies and the expansion of treatment guidelines recommending IL-23 inhibitors for moderate-to-severe plaque psoriasis have further boosted Tremfya’s market share in this segment.

Distribution Channel Insights

Based on the Distribution Channel, Hospital Pharmacies emerged as the dominant segment in the Global Tremfya Market in 2024. This dominance is supported by the growing reliance on hospital-based care for initiating and managing biologic treatments. Tremfya, being a prescription-only biologic therapy, often requires initial administration under medical supervision to ensure proper dosing, monitor patient response, and manage potential adverse effects. Hospitals serve as primary hubs for diagnosing moderate-to-severe plaque psoriasis and psoriatic arthritis, where dermatologists and rheumatologists prescribe Tremfya as part of comprehensive treatment plans. The availability of specialized healthcare professionals, advanced diagnostic facilities, and integrated patient support services within hospital settings has strengthened the preference for hospital pharmacies. Additionally, hospital procurement channels ensure secure storage, proper handling, and compliance with cold chain requirements for biologics, which is essential for maintaining product efficacy.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Tremfya Market in 2024. This is primarily driven by a combination of high disease prevalence, well-established healthcare infrastructure, and strong adoption of biologic therapies. The United States, as the largest contributor, has a significant population of patients suffering from moderate-to-severe plaque psoriasis and psoriatic arthritis, creating a robust demand for advanced treatments like Tremfya. Widespread awareness among healthcare professionals regarding the efficacy and safety of IL-23 inhibitors has led to higher prescription rates, while patients increasingly seek therapies that offer long-term disease control with convenient dosing schedules. The region benefits from favorable reimbursement policies and insurance coverage for biologics, reducing out-of-pocket expenses and making treatments more accessible. Advanced hospital and specialty pharmacy networks ensure proper storage, handling, and distribution of biologics, further supporting market growth. Strong presence of key market players, such as Johnson & Johnson, and ongoing investments in clinical trials and pipeline expansions enhance product availability and patient trust.

Recent Developments

• In March 2025, the U.S. FDA approved TREMFYA (guselkumab), Johnson & Johnson’s IL-23 inhibitor, for adult patients with moderately to severely active Crohn’s disease. TREMFYA is the first IL-23 inhibitor offering both subcutaneous and intravenous induction options. This approval follows its earlier clearance for ulcerative colitis and marks it as the first fully-human monoclonal antibody that blocks IL-23 while binding to CD64, a receptor on cells producing IL-23, targeting a key driver of immune-mediated gastrointestinal disorders.
• In March 2025, Johnson & Johnson announced that Icotrokinra demonstrated significant improvements in managing moderate-to-severe plaque psoriasis, achieving rapid and sustained reductions in Psoriasis Area and Severity Index (PASI) scores. The therapy exhibited a strong safety profile and was well tolerated across the study population, indicating a favorable benefit-risk balance. These findings position Icotrokinra as a potential new standard of care for patients seeking effective and durable plaque psoriasis treatment, reflecting the company’s commitment to advancing innovative dermatology therapies.
• In September 2024, the U.S. FDA approved TREMFYA (guselkumab) for adults with moderately to severely active ulcerative colitis, reinforcing Johnson & Johnson’s position in inflammatory bowel disease. TREMFYA is the first fully-human monoclonal antibody that both blocks IL-23 and binds to CD64, targeting key immune pathways driving UC.
• In May 2024, Johnson & Johnson reported positive outcomes from a Phase 3 clinical study of Tremfya in patients with Crohn’s disease. The results revealed that Tremfya outperformed ustekinumab in reducing disease severity among moderate-to-severe cases, underscoring its robust efficacy in gastrointestinal inflammatory disorders. This milestone strengthens Tremfya’s therapeutic profile beyond dermatology, highlighting its potential as a key biologic treatment for inflammatory bowel disease.
• In October 2023, Janssen Pharmaceuticals, a Johnson & Johnson company, presented new research on TREMFYA (guselkumab) and the investigational oral peptide JNJ-2113 at the European Academy of Dermatology and Venereology (EADV) Congress in Berlin. Key findings from the Phase 3b GUIDE trial showed that early intervention with TREMFYA in patients with short-duration psoriasis resulted in high PASI responses, highlighting the benefits of tailored treatment strategies. Additionally, Phase 2 FRONTIER 1 trial data for JNJ-2113 demonstrated systemic pharmacodynamic responses, supporting its potential as a targeted therapy for moderate to severe plaque psoriasis.

Key Market Players

• Johnson & Johnson Services, Inc.
• Coherus BioSciences
• Amgen Inc.
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Pfizer Inc.
• AstraZeneca plc
• Sanofi S.A.
• Bristol-Myers Squibb

Report Scope:

In this report, the Global Tremfya Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Tremfya Market, By Application:

o   Plaque Psoriasis

o   Psoriatic Arthritis (PsA)

o   Others

• Tremfya Market, By Distribution Channel:

o   Hospital Pharmacies

o   Retail Pharmacies

o   Online Pharmacies

• Tremfya Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Tremfya Market.

Available Customizations:

Global Tremfya Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Tremfya Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]